Completed

The Clinical and Pathological Significance of Allelic Imbalance of 8p in Patients With Colorectal Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Genetic Data

+ genetic Data

Collected from today forward - Prospective
GeneticDNA Samples
Who is being recruted

Colonic Diseases+9

+ Digestive System Diseases

+ Digestive System Neoplasms

Until 69 Years
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: February 1999
See protocol details

Summary

Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 13, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 1999

Actual date on which the first participant was enrolled.

OBJECTIVES: Determine the adverse prognostic significance of 8p allelic imbalance (AI) in patients with colon cancer. Determine if patient prognosis is dependent on the region of 8p AI. Perform fine mapping studies to further localize the putative tumor suppressor gene(s) on 8p. Perform multicolor FISH to examine the role that 8p loss and 8q gain play in the prognosis of patients whose tumors exhibit 8p AI. OUTLINE: Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.

NCT00003833
Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 13, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

598 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Until 69 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Colonic DiseasesDigestive System DiseasesDigestive System NeoplasmsGastrointestinal DiseasesGastrointestinal NeoplasmsIntestinal DiseasesIntestinal NeoplasmsNeoplasmsNeoplasms by SiteRectal DiseasesColonic NeoplasmsColorectal Neoplasms

Criteria

DISEASE CHARACTERISTICS: Diagnosis of resectable stage II or III adenocarcinoma of the colon Participated in NCCTG-914653 DNA extracted from both normal and tumor tissue PATIENT CHARACTERISTICS: Age Under 70

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 59 locations

St. Mary's/Duluth Clinic Health System

Duluth, United StatesOpen St. Mary's/Duluth Clinic Health System in Google Maps

Tom Baker Cancer Center - Calgary

Calgary, Canada

Lethbridge Cancer Clinic

Lethbridge, Canada

Nanaimo Cancer Clinic

Nanaimo, Canada
Completed59 Study Centers